Significant biosimilar activities this week include: 30 Sep 22 | EU | EMA accepts Biogen tocilizumab MAA Biogen announced that the EMA has accepted the MAA for BIIB800...
PiPCast™ | Expedited Patent Prosecution in Australia and New Zealand
The Australian High Court will have an experienced intellectual property judge on its bench, with the appointment of Justice Jayne Jagot to the bench announced on Thursday 29...
Significant biosimilar activities this week include: 22 Sep 22 | CH | STADA launches Alvotech’s Hukyndra® (100mg/mL adalimumab) in Switzerland Alvotech and STADA announced the...
Pearce IP is very proud to announce that its CEO and Executive Lawyer, Patent Attorney and Trade Mark Attorney Naomi Pearce has been honoured as the 2022 Patent Lawyer of the...
Significant biosimilar activities this week include: 07 Sep 22 | Celltrion’s ustekinumab biosimilar Ph III trials Yonhap News Agency reported that Celltrion’s ustekinumab...
In this PiPCast®, Naomi Pearce and Kate Legge walk through the key IP strategies biosimilars companies are using to enable market entry globally, and canvas biosimilar litigation in Australian courts. They also discuss recent litigation settlement activity and lessons learnt.
Significant biosimilar activities this week include: 25 Aug 22 | JP | Lupin and I’rom sign licence for denosumab in Japan Lupin announced that it has entered into an exclusive...
Significant biosimilar activities this week include: 12 Aug 22 | US | Alvotech, Mylan & others file amicus curiae briefs in support of Teva’s skinny label case Alvotech,...
In this PiPCast™, Kate Legge and Grant Shoebridge discuss whether a patent inventor must be human or can include artificial intelligence systems in Australia, and look to the future legal developments in this space.
Significant biosimilar activities this week include: 23 Aug 22 | Amgen announces the results of Ph III eculizumab trials Amgen announced the results of a Ph III study evaluating...
In this PiPCast®, Pearce IP’s HR Director, Adele Chadwick, speaks to Executives Naomi Pearce and Katrina Crooks about diversity and inclusion – what this means to Pearce IP, and the impact that diversity and inclusion have on a legal practice and business.
Even the High Court of Australia could not come to a majority decision on the thorny question of the patentability of computer-implemented inventions in its highly anticipated...
Significant biosimilar activities this week include: 11 Aug 22 | ALX Oncology initiates Ph II trials of evorpacept in combination with cetuximab and pembrolizumab ALX Oncology...
Pearce IP’s Katrina Crooks speaks to Naomi Pearce about non-use applications and how the adage “use it or lose it” applies to trade marks in Australia.
Significant biosimilar activities this week include: 27 Jul 22 | CN | Ph III trial shows Qila’s denosumab biosimilar improves bone mineral density It has been reported that a Ph...
In this PiPCast® Katrina Crooks speaks to Naomi Pearce about case management strategies for Federal Court litigation in Australia, with a focus on patent litigation. Learn about the latest case management trends and why effective case management is crucial.
Significant biosimilar activities this week include: 27 Jul 22 | AU | Viatris (Mylan) seeks PBS listing for etanercept biosimilar Alphapharm (Viatris’ Australian subsidiary) has...
In the field of medicinal cannabis, plant varietal or cultivar names that are protected by a registered right such as a PBR (plant breeder right) are often mirrored in commercial...
Pearce IP’s Grant Shoebridge speaks to Naomi Pearce about the hot topic in Australian patent law: Patent Term Extension (PTE) in Australia
Chimeric Antigen Receptor (CAR)-T cell therapy is a pioneering technology that is successfully changing the way we think about the treatment of cancer, in particular blood...
Introduction Plant based protein products are already a well established destination in the supermarket aisle. Australia is reportedly the third fastest growing market for such...
Significant biosimilar activities this week include: 25 Jul 22 | US | FDA accepts ABLA for natalizumab biosimilar Sandoz announced that the FDA has accepted its ABLA for a...
We are proud to announce that Pearce IP and its CEO have been shortlisted for three awards at the APAC 2022 Women in Business Law Awards, with the winners to be announced on...
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.
